827 results on '"Chang, Sam S."'
Search Results
2. Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer
3. Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin[FIGURE DASH]Unresponsive Nonmuscle-Invasive Bladder Cancer
4. The Role of Alumni Networks and Career Advising in Early Career Stability of Urologists: Results of a Multi-institutional Study
5. Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer
6. Intravesical Therapy Compared to Radical Cystectomy Among Patients With Non-Muscle Invasive Bladder Cancer Requiring Additional Treatment After Induction BCG
7. Catching Those Who Fall Through the Cracks: Integrating a Follow-Up Process for Emergency Department Patients with Incidental Radiologic Findings
8. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non–muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis
9. Implementation of a comprehensive prehabilitation program for patients undergoing radical cystectomy
10. Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer.
11. Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review
12. Role and Indications of Organ-Sparing “Radical” Cystectomy: The Importance of Careful Patient Selection and Counseling
13. Conduit Urinary Diversion
14. Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial
15. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
16. Intravesical oncolytic virotherapy and immunotherapy for non‐muscle‐invasive bladder cancer mouse model.
17. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer
18. Increasing Use of Observation among Men at Low Risk for Prostate Cancer Mortality
19. Lack of P16ink4a Over Expression in Penile Squamous Cell Carcinoma is Associated with Recurrence after Lymph Node Dissection
20. Impact of Complications and Hospital-Free Days on Health Related Quality of Life 1 Year after Radical Cystectomy
21. The Influence of Access Related Factors on Adherence to Clinical Practice Guidelines for Muscle Invasive Bladder Cancer
22. Alvimopan, a Peripherally Acting μ-Opioid Receptor Antagonist, is Associated with Reduced Costs after Radical Cystectomy: Economic Analysis of a Phase 4 Randomized, Controlled Trial
23. Retroperitoneal versus transperitoneal robotic-assisted laparoscopic partial nephrectomy: a matched-pair, bicenter analysis with cost comparison using time-driven activity-based costing
24. Re: Clinical Significance of Preoperative C-Reactive Protein and Squamous Cell Carcinoma Antigen Levels in Patients with Penile Squamous Cell Carcinoma
25. Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer
26. Re: The Impact of Re-Transurethral Resection on Clinical Outcomes in a Large Multicentre Cohort of Patients with T1 High-Grade/Grade 3 Bladder Cancer Treated with bacille Calmette-Guérin
27. Re: Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances
28. Re: Increasing Age is Not Associated with Toxicity Leading to Discontinuation of Treatment in Patients with Urothelial Non-Muscle-Invasive Bladder Cancer Randomised to Receive 3 Years of Maintenance bacille Calmette-Guérin: Results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group Study 30911
29. Recent Changes in Prostate Cancer Screening Practices and Epidemiology
30. Re: Orthotopic Neobladder vs. Ileal Conduit Urinary Diversion: A Long-Term Quality-of-Life Comparison
31. Re: Propensity Score Analysis of Radical Cystectomy versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic
32. Re: The Health Effects of Electronic Cigarettes
33. Association between Preoperative Albumin Levels and Length of Stay after Radical Cystectomy
34. Re: Anti-Inflammatory Use May Not Negatively Impact Oncologic Outcomes following Intravesical BCG for High-Grade Non-Muscle-Invasive Bladder Cancer
35. Re: Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-Muscle Invasive Bladder Cancer Patients
36. Re: Clinical and Therapeutic Factors Associated with Adverse Pathological Outcomes in Clinically Node-Negative Patients Treated with Neoadjuvant Cisplatin-Based Chemotherapy and Radical Cystectomy
37. Effects of Specialist Palliative Care for Patients Undergoing Major Abdominal Surgery for Cancer: A Randomized Clinical Trial.
38. Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline.
39. Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma
40. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer
41. Re: Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial
42. Re: Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can we Actually Improve the Surgical Quality?
43. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
44. Re: New Strategies in Bladder Cancer: A Second Coming for Immunotherapy
45. Re: Prediction Model for Recurrence Probabilities after Intravesical Chemotherapy in Patients with Intermediate-Risk Non-Muscle-Invasive Bladder Cancer, Including External Validation
46. Re: Long-Term Outcome of Patients with Frequently Recurrent Non-Muscle-Invasive Bladder Carcinoma Treated with One Perioperative plus Four Weekly Instillations of Mitomycin C followed by Monthly bacillus Calmette-Guérin (BCG) or Alternating BCG and Interferon-α2b Instillations: Prospective Randomised FinnBladder-4 Study
47. Re: Benefits of Adjuvant Chemotherapy for Bladder Cancer
48. Re: DaPeCa-1: Diagnostic Accuracy of Sentinel Lymph Node Biopsy in 222 Patients with Penile Cancer at Four Tertiary Referral Centres—A National Study from Denmark
49. Re: Comprehensive Genomic Profiling of 295 Cases of Clinically Advanced Urothelial Carcinoma of the Urinary Bladder Reveals a High Frequency of Clinically Relevant Genomic Alterations
50. Re: Utility and Significance of Ureteric Frozen Section Analysis during Radical Cystectomy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.